Inventiva SA
IVA4.440USD
+0.060+1.37%
收盘 12/24, 13:00（美东）报价延迟15分钟
0.00总市值
--市盈率 TTM
关于 Inventiva SA 公司
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Inventiva SA简介
公司代码IVA
公司名称Inventiva SA
上市日期Feb 15, 2017
CEOObenshain (Andrew)
员工数量- -
证券类型Depository Receipt
年结日- -
公司地址50 rue de Dijon
城市DAIX
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编21121
电话33380447500
网址https://inventivapharma.com/
公司代码IVA
上市日期Feb 15, 2017
CEOObenshain (Andrew)
Inventiva SA公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Andre Turenne
Andre Turenne
Independent Director
Independent Director
--
--
Dr. Jason Campagna, M.D., Ph.D.
Dr. Jason Campagna, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Pascaline Clerc
Ms. Pascaline Clerc
Executive Vice President - Strategy and Corporate Affairs
Executive Vice President - Strategy and Corporate Affairs
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月21日 周五
更新时间: 11月21日 周五
持股股东
股东类型
持股股东
持股股东
占比
Samsara BioCapital, LLC
3.73%
Yiheng Capital Management, L.P.
1.90%
New Enterprise Associates (NEA)
1.05%
BVF Partners L.P.
0.49%
Millennium Management LLC
0.08%
其他
92.74%
持股股东
持股股东
占比
Samsara BioCapital, LLC
3.73%
Yiheng Capital Management, L.P.
1.90%
New Enterprise Associates (NEA)
1.05%
BVF Partners L.P.
0.49%
Millennium Management LLC
0.08%
其他
92.74%
股东类型
持股股东
占比
Venture Capital
4.78%
Investment Advisor
2.01%
Hedge Fund
0.57%
Research Firm
0.02%
Investment Advisor/Hedge Fund
0.02%
其他
92.59%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
21
4.95M
5.18%
+27.37K
2025Q2
19
4.87M
5.09%
-661.07K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
2023Q3
22
4.86M
11.53%
-1.45M
2023Q2
24
4.83M
11.47%
-1.47M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Yiheng Capital Management, L.P.
2.64M
2.76%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
1.46M
1.53%
--
--
Jun 30, 2025
BVF Partners L.P.
686.04K
0.72%
--
--
Jun 30, 2025
Commonwealth Financial Network
54.32K
0.06%
-169.00
-0.31%
Jun 30, 2025
Morgan Stanley & Co. International Plc
2.10K
0%
+2.10K
--
Jun 30, 2025
Wealth Enhancement Advisory Services, LLC
16.56K
0.02%
+5.84K
+54.53%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Inventiva SA的前五大股东是谁？
Inventiva SA 的前五大股东如下：
Yiheng Capital Management, L.P.持有股份：2.64M，占总股份比例：2.76%。
New Enterprise Associates (NEA)持有股份：1.46M，占总股份比例：1.53%。
BVF Partners L.P.持有股份：686.04K，占总股份比例：0.72%。
Commonwealth Financial Network持有股份：54.32K，占总股份比例：0.06%。
Morgan Stanley & Co. International Plc持有股份：2.10K，占总股份比例：0.00%。
Yiheng Capital Management, L.P.持有股份：2.64M，占总股份比例：2.76%。
New Enterprise Associates (NEA)持有股份：1.46M，占总股份比例：1.53%。
BVF Partners L.P.持有股份：686.04K，占总股份比例：0.72%。
Commonwealth Financial Network持有股份：54.32K，占总股份比例：0.06%。
Morgan Stanley & Co. International Plc持有股份：2.10K，占总股份比例：0.00%。
Inventiva SA的前三大股东类型是什么？
Inventiva SA 的前三大股东类型分别是：
Samsara BioCapital, LLC
Yiheng Capital Management, L.P.
New Enterprise Associates (NEA)
Samsara BioCapital, LLC
Yiheng Capital Management, L.P.
New Enterprise Associates (NEA)
有多少机构持有Inventiva SA(IVA)的股份？
截至2025Q3，共有21家机构持有Inventiva SA的股份，合计持有的股份价值约为4.95M，占公司总股份的5.18%。与2025Q2相比，机构持股有所增加，增幅为0.09%。
哪个业务部门对Inventiva SA的收入贡献最大？
在--，--业务部门对Inventiva SA的收入贡献最大，创收--，占总收入的--%。
